Initial Treatment for Newly Diagnosed Deep Vein Thrombosis (DVT)

Initial Anticoagulation Options

The American College of Chest Physicians recommends initial treatment for newly diagnosed DVT with parenteral anticoagulation using low-molecular-weight heparin (LMWH), fondaparinux, intravenous unfractionated heparin (UFH), or subcutaneous UFH, or direct oral anticoagulant (DOAC) therapy with rivaroxaban 1, 2
LMWH is suggested over IV UFH (Grade 2C) and over SC UFH (Grade 2B) due to its more predictable pharmacokinetics and reduced need for monitoring 2, 4
Once-daily LMWH administration is suggested over twice-daily administration (Grade 2C) 4
Rivaroxaban can be used as monotherapy without initial parenteral anticoagulation 1

For patients with high clinical suspicion of DVT, treatment with parenteral anticoagulants is suggested while awaiting diagnostic test results (Grade 2C) 5, 6
For intermediate clinical suspicion, parenteral anticoagulation is suggested if diagnostic test results will be delayed more than 4 hours (Grade 2C) 5, 6
For low clinical suspicion, withholding anticoagulation is suggested if test results are expected within 24 hours (Grade 2C) 5, 6

For proximal DVT, anticoagulation is recommended for a minimum of 3 months (Grade 1B) 1, 6
Early initiation of vitamin K antagonist (VKA) therapy is recommended on the same day as parenteral therapy is started 4
Parenteral anticoagulation should be continued for a minimum of 5 days and until the INR is ≥2.0 for at least 24 hours (Grade 1B) 4

For DVT associated with active cancer, extended anticoagulation therapy is recommended (Grade 1B) 1, 6
An oral factor Xa inhibitor (apixaban, edoxaban, rivaroxaban) is recommended over LMWH for cancer patients, according to the American Society of Clinical Oncology 1

All patients should receive a minimum of 3 months of anticoagulation, as recommended by the American College of Chest Physicians 1
For provoked DVT related to a major reversible risk factor, 3 months of therapy is recommended (Grade 1B) 1
For unprovoked DVT, extended therapy should be considered if bleeding risk is low or moderate (Grade 2B) 1